Silvan Turkcan
Stock Analyst at Citizens
(2.72)
# 4,201
Out of 5,182 analysts
6
Total ratings
75%
Success rate
18.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Turkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HURA TuHURA Biosciences | Initiates: Market Outperform | $9 | $2.16 | +316.67% | 1 | Apr 27, 2026 | |
| CELC Celcuity | Initiates: Market Outperform | $150 | $125.85 | +19.19% | 1 | Apr 27, 2026 | |
| CLLS Cellectis | Reiterates: Market Outperform | $8 | $4.02 | +99.00% | 1 | Apr 14, 2026 | |
| RLAY Relay Therapeutics | Maintains: Market Outperform | $15 → $17 | $13.80 | +23.19% | 1 | Mar 17, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $21 → $28 | $13.46 | +108.02% | 1 | Mar 3, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Market Outperform | $86 → $80 | $50.25 | +59.20% | 1 | Jan 30, 2026 |
TuHURA Biosciences
Apr 27, 2026
Initiates: Market Outperform
Price Target: $9
Current: $2.16
Upside: +316.67%
Celcuity
Apr 27, 2026
Initiates: Market Outperform
Price Target: $150
Current: $125.85
Upside: +19.19%
Cellectis
Apr 14, 2026
Reiterates: Market Outperform
Price Target: $8
Current: $4.02
Upside: +99.00%
Relay Therapeutics
Mar 17, 2026
Maintains: Market Outperform
Price Target: $15 → $17
Current: $13.80
Upside: +23.19%
Intellia Therapeutics
Mar 3, 2026
Maintains: Market Outperform
Price Target: $21 → $28
Current: $13.46
Upside: +108.02%
CRISPR Therapeutics AG
Jan 30, 2026
Maintains: Market Outperform
Price Target: $86 → $80
Current: $50.25
Upside: +59.20%